UGT1A1 and colorectal cancer: Recently, a study in Japanese colorectal cancer patients revealed that reduction of the initial irinotecan dose from 150 mg/m2 to 120 mg/m2 results in a safe and efficient therapy in UGT1A1 homozygote variant allele carriers[30].